Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL Infant & Toddler: Infigratinib in Infants and Young Children With Achondroplasia
NCT07169279Phase 2Recruiting
- Sponsor
- QED Therapeutics
- Start
- Nov 2025
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of infigratinib in achondroplasia (ACH), sponsored by QED Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT07169279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169279.